EMEA-001407-PIP03-20
Key facts
| Invented name |
Opdivo
|
| Active substance |
nivolumab
|
| Therapeutic area |
Oncology
|
| Decision number |
P/0280/2020
|
| PIP number |
EMEA-001407-PIP03-20
|
| Pharmaceutical form(s) |
Solution for injection
|
| Condition(s) / indication(s) |
Treatment of all conditions in the category of malignant neoplasms (except central nervous system neoplasms, haematopoietic and lymphoid tissue neoplasms other than Hodgkin lymphoma)
|
| Route(s) of administration |
Subcutaneous use
|
| Contact for public enquiries |
Bristol-Myers Squibb Pharma EEIG
E-mail: medical.information@bms.com |
| Decision type |
W: decision granting a waiver in all age groups for all conditions or indications
|